25th Sep 2009 17:20
Director/PDMR Shareholding
September 25, 2009 - Shire plc , the global specialty biopharmaceutical company (the "Company"), announces that on September 25, 2009, it was notified by Mr Matthew Emmens, Chairman of the Company, of the exercise, on September 24, 2009, of an option over 927,731 Shire ordinary shares of 5p ("Shares") at an exercise price of 3.6825. Mr Emmens chose to use a net settled cashless exercise facility run by the Company which resulted in a total of 606,673 Shares being allotted to him. The option over the remaining 321,058 Shares lapsed.
The Company was also notified by Mr Emmens on September 25, 2009 of the following sale of Shares:
Date of sale Number of Shares sold Average sale price September 24, 2009 191,469 GBP10.641 September 24, 2009 222,566 GBP10.5972 September 25, 2009 192,638 GBP10.706
Following this transaction, Mr Emmens holds 92,874 Shares and 60,861 ADSs and options over 590,834 Shares. He also holds awards of Stock Appreciation Rights, Performance Shares and Restricted Shares over 383,408 ADSs. One ADS is equal to three Shares.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations Clea Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 617 551 9715 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
2Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
vendorRelated Shares:
Shire